Shares of Ionis Pharmaceuticals (IONS) are under pressure on Tuesday after the company announced that its partner Roche (RHHBY) decided to discontinue dosing in the Phase 3 GENERATION HD1 study of tominersen in manifest Huntington’s disease. While Cowen analyst… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3271425/-Ionis-Pharmaceuticals-slides-as-Wall-Street-digests-HD-program-setback)
previous post
next post